Skip to main content

EL FENOTIPO SILENTE DE MYCOBACTERIUM TUBERCULOSIS: PERSISTENCIA Y LATENCIA

SAF2017-84839-C2-1-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE ZARAGOZA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mycobacterial aminoglycoside acetyltransferases: A little of drug resistance, and a lot of other roles

  • Sanz-García, Fernando
  • Anoz-Carbonell, Ernesto
  • Pérez-Herrán, Esther
  • Martín, Carlos
  • Lucía, Ainhoa
  • Rodrigues, Liliana
  • Aínsa, José A.
© 2019 Sanz-García, Anoz-Carbonell, Pérez-Herrán, Martín, Lucía, Rodrigues and Aínsa., Aminoglycoside acetyltransferases are important determinants of resistance to aminoglycoside antibiotics in most bacterial genera. In mycobacteria, however, aminoglycoside acetyltransferases contribute only partially to aminoglycoside susceptibility since they are related with low level resistance to these antibiotics (while high level aminoglycoside resistance is due to mutations in the ribosome). Instead, aminoglycoside acetyltransferases contribute to other bacterial functions, and this can explain its widespread presence along species of genus Mycobacterium. This review is focused on two mycobacterial aminoglycoside acetyltransferase enzymes. First, the aminoglycoside 2′-N-acetyltransferase [AAC(2′)], which was identified as a determinant of weak aminoglycoside resistance in M. fortuitum, and later found to be widespread in most mycobacterial species; AAC(2′) enzymes have been associated with resistance to cell wall degradative enzymes, and bactericidal mode of action of aminoglycosides. Second, the Eis aminoglycoside acetyltransferase, which was identified originally as a virulence determinant in M. tuberculosis (enhanced intracellular survival); Eis protein in fact controls production of pro-inflammatory cytokines and other pathways. The relation of Eis with aminoglycoside susceptibility was found after the years, and reaches clinical significance only in M. tuberculosis isolates resistant to the second-line drug kanamycin. Given the role of AAC(2′) and Eis proteins in mycobacterial biology, inhibitory molecules have been identified, more abundantly in case of Eis. In conclusion, AAC(2′) and Eis have evolved from a marginal role as potential drug resistance mechanisms into a promising future as drug targets., FS-G and EA-C are recipients of FPU fellowships from the Spanish Ministry of Economy and Competitivity. JA acknowledges funding from the European Comission [More Medicines for Tuberculosis (MM4TB) grant 260872] and the Spanish Ministry of Economy and Competitivity (grants SAF-2013-48971-C2-2-R and SAF2017-84839-C2-1-R).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nanotechnology-based targeted drug delivery: An emerging tool to overcome tuberculosis

  • Baranyai, Zsuzsa
  • Soria-Carrera, Héctor
  • Alleva, María
  • Millán-Placer, Ana C.
  • Lucía, Ainhoa
  • Martín-Rapún, Rafael
  • Aínsa, José A.
  • Fuente, Jesús M. de la
The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial-loaded nanocarriers are avidly taken up by macrophages, the main cells hosting Mycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment., This work was supported by the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant Agreement No. 842652, the Spanish MICINN projects (Grant Nos. BIO2017-84246-C2-1-R, SAF2017-84839-C2-1-R, and CTQ2015-66869-P), and by the Gobierno de Aragón (Diputación General de Aragón–Fondo Social Europeo). R.M.-R. acknowledges MICINN for funding through the Ramón y Cajal Program (Grant No. RYC-2013-12570). H.S.-C. and A.C.M.-P. are grateful for FPU predoctoral contracts from Ministerio de Educación Cultura y Deporte (Spain) and M.A. is grateful for a predoctoral contract from Gobierno de Aragón (Diputación General de Aragón–Fondo Social Europeo)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA)

  • Hibbitts, Alan
  • Lucía, Ainhoa
  • Serrano-Sevilla, Inés
  • De Matteis, Laura
  • McArthur, Michael
  • Fuente, Jesús M. de la
  • Aínsa, José A.
  • Navarro, Fabrice
Bacterial resistance to antibiotics is widely regarded as a major public health concern with last resort MRSA treatments like vancomycin now encountering resistant strains. TFDs (Transcription Factor Decoys) are oligonucleotide copies of the DNA-binding sites for transcription factors. They bind to and sequester the targeted transcription factor, thus inhibiting transcription of many genes. By developing TFDs with sequences aimed at inhibiting transcription factors controlling the expression of highly conserved bacterial cell wall proteins, TFDs present as a potential method for inhibiting microbial growth without encountering typical resistance mechanisms. However, the efficient protection and delivery of the TFDs inside the bacterial cells is a critical step for the success of this technology. Therefore, in our study, specific TFDs against S. aureus were complexed with two different types of nanocarriers: cationic nanostructured lipid carriers (cNLCs) and chitosan-based nanoparticles (CS-NCs). These TFD-carrier nanocomplexes were characterized for size, zeta potential and TFD complexation or loading efficiency in a variety of buffers. In vitro activity of the nanocomplexes was examined alone and in combination with vancomycin, first in methicillin susceptible strains of S. aureus with the lead candidate advancing to tests against MRSA cultures. Results found that both cNLCs and chitosan-based carriers were adept at complexing and protecting TFDs in a range of physiological and microbiological buffers up to 72 hours. From initial testing, chitosan-TFD particles demonstrated no visible improvements in effect when co-administered with vancomycin. However, co-delivery of cNLC-TFD with vancomycin reduced the MIC of vancomycin by over 50% in MSSA and resulted in significant decreases in viability compared with vancomycin alone in MRSA cultures. Furthermore, these TFD-loaded particles demonstrated very low levels of cytotoxicity and haemolysis in vitro. To our knowledge, this is the first attempt at a combined antibiotic/oligonucleotide-TFD approach to combatting MRSA and, as such, highlights a new avenue of MRSA treatment combining traditional small molecules drugs and bacterial gene inhibition., This work was undertaken as part of the Nano-therapeutics for Antibiotic Resistant Emerging Bacterial Pathogens (NAREB) European research network supported by the EU FP7 under grant agreement 604237. JMF, LM and ISS thank the financial support from the Ministerio de Ciencia, Innovación y Universidades (BIO2017-84246-C2-1-R) and Gobierno de Aragón and Fondos Feder (Bionanosurf E15_17R). ISS acknowledges Ministerio de Economía y Competitividad del Gobierno de España for her FPI grant (BES-2015-071304). JAA ackowledges funding from the Ministerio de Ciencia, Innovación y Universidades (SAF2017-84839-C2-2-R) and Gobierno de Aragón and Fondos Feder (Grupo de Genética de Micobacterias B35 17R)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mycobacterial aminoglycoside acetyltransferases: a little of drug resistance, and a lot of other roles

  • Sanz-García, F.
  • Anoz-Carbonell, E.
  • Pérez-Herrán, E.
  • Martín, C.
  • Lucía, A.
  • Rodrigues, L.
  • Aínsa, J.A.
Aminoglycoside acetyltransferases are important determinants of resistance to aminoglycoside antibiotics in most bacterial genera. In mycobacteria, however, aminoglycoside acetyltransferases contribute only partially to aminoglycoside susceptibility since they are related with low level resistance to these antibiotics (while high level aminoglycoside resistance is due to mutations in the ribosome). Instead, aminoglycoside acetyltransferases contribute to other bacterial functions, and this can explain its widespread presence along species of genus Mycobacterium. This review is focused on two mycobacterial aminoglycoside acetyltransferase enzymes. First, the aminoglycoside 2'-N-acetyltransferase [AAC(2')], which was identified as a determinant of weak aminoglycoside resistance in M. fortuitum, and later found to be widespread in most mycobacterial species; AAC(2') enzymes have been associated with resistance to cell wall degradative enzymes, and bactericidal mode of action of aminoglycosides. Second, the Eis aminoglycoside acetyltransferase, which was identified originally as a virulence determinant in M. tuberculosis (enhanced intracellular survival); Eis protein in fact controls production of pro-inflammatory cytokines and other pathways. The relation of Eis with aminoglycoside susceptibility was found after the years, and reaches clinical significance only in M. tuberculosis isolates resistant to the second-line drug kanamycin. Given the role of AAC(2') and Eis proteins in mycobacterial biology, inhibitory molecules have been identified, more abundantly in case of Eis. In conclusion, AAC(2') and Eis have evolved from a marginal role as potential drug resistance mechanisms into a promising future as drug targets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Nanotechnology-Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

  • Baranyai, Z.
  • Soria-Carrera, H.
  • Alleva, M.
  • Millan-Placer, A.C.
  • Lucia, A.
  • Martin-Rapun, R.
  • Ainsa, J.A.
  • de la Fuente, J.M.
The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial-loaded nanocarriers are avidly taken up by macrophages, the main cells hostingMycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment. La aparición y la rápida propagación de cepas de tuberculosis (TB) resistentes a los medicamentos, una de las enfermedades infecciosas más mortales, representan una grave amenaza para la salud pública y aumentan la necesidad de tratamientos más breves, menos tóxicos y más eficaces. El desarrollo de nuevos fármacos es difícil y, a menudo, se asocia con efectos secundarios, por lo que la nanotecnología se ha convertido en una herramienta para mejorar los tratamientos actuales y rescatar fármacos que tienen una toxicidad elevada o una solubilidad deficiente. Debido a su tamaño y química de superficie, los nanoportadores cargados de antimicrobianos son absorbidos con avidez por los macrófagos, las principales células que albergan Mycobacterium tuberculosis.. Los macrófagos se reclutan continuamente en las áreas infectadas, pueden transportar medicamentos con ellos, lo que hace que la focalización pasiva sea una buena estrategia para el tratamiento de la TB. La focalización activa (decoración de la superficie de los nanoportadores con ligandos específicos de los receptores mostrados por los macrófagos) aumenta aún más la concentración local del fármaco y, por lo tanto, la eficacia del tratamiento. Aunque en estudios in vivo, los nanotransportadores a menudo se administran por vía intravenosa para evitar dosis inexactas en animales, la traducción a humanos requiere vías más convenientes, como la administración pulmonar u oral. Este informe destaca la importancia y el progreso de la administración pulmonar, las estrategias de orientación pasiva y activa hacia los reservorios de bacterias para superar los desafíos en el tratamiento de la TB.